New agreement supersedes the collaboration agreement entered in 2012 GSK retains non-exclusive right to use PRINT for pre-clinical research for inhaled delivery Liquidia can apply PRINT to any inhaled application other than identified GSK proprietary molecules MORRISVILLE, N.C.
Clarified path to potential launch YUTREPIA upon resolution of litigation in late-2023 to mid-2024 Fortified financial position through 2024 Company to host webcast today at 8:30 a.m. ET MORRISVILLE, N.C. , March 16, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the
MORRISVILLE, N.C. , March 09, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its full year 2022 financial results on Thursday, March 16, 2023 . The company will host a webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a
PTAB rejects UTHR’s request for rehearing of its decision in the inter partes review of the ‘793 Patent (‘793 IPR) PTAB clarified grounds upon which it based its finding that the cited publications, which invalidated the claims, constituted prior art Company reaffirms expectation of legal
MORRISVILLE, N.C. , Feb. 02, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced the grant of inducement stock options exercisable for an aggregate of 10,000 shares of Liquidia’s common stock to newly hired non-executive employees under the Liquidia Corporation 2022
Extends cash-runway through at least 2024 Provides flexibility to accelerate launch preparations timed with success in litigation MORRISVILLE, N.C. , Jan. 09, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) ( Liquidia or the Company) announced today that it has entered into a Revenue
Liquidia and Sandoz will collaborate with Mainbridge Health Partners to develop a new infusion pump Liquidia and Sandoz have also extended the term of their promotion agreement for Treprostinil Injection until 2032 MORRISVILLE, N.C. , Dec. 05, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:
Company to host webcast and conference call today at 8:30 a.m. ET MORRISVILLE, N.C. , Nov. 08, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today reported financial results for the third quarter ended September 30, 2022 .
MORRISVILLE, N.C. , Nov. 01, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its third quarter 2022 financial results on Tuesday, November 8, 2022 . The company will host a conference call and webcast at 8:30 a.m.
MORRISVILLE, N.C. , Oct. 27, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that on October 26, 2022 , the Precedential Opinion Panel (POP) of the United States Patent and Trademark Office (USPTO) denied a request by United Therapeutics (UTC) to review the decision by